In light of our new findings, it is likely that molecularly targeted therapies, such as KRAS inhibitors, BRAF inhibitors, angiogenesis inhibitors, and immune checkpoint inhibitors, should be validated for treating advanced-stage duodenal adenocarcinoma, similar to the studies of colorectal cancer. The gene discussed is BRAF; the disease is colorectal cancer.